ZepboundvsSaxenda

Zepbound's active drug, tirzepatide, is a once-weekly injection that activates two gut-hormone receptors at once: GLP-1 and GIP. This "dual agonist" design is what sets it apart from GLP-1-only drugs like Wegovy. By mimicking these hormones, it curbs appetite, increases fullness, and slows how fast the stomach empties, so most people eat less and feel satisfied longer. It also improves how the body releases insulin and handles blood sugar. The result is sustained calorie reduction without the constant hunger that derails many diets.

Saxenda's active ingredient is liraglutide, a GLP-1 receptor agonist that mimics glucagon-like peptide-1, a natural gut hormone released after eating. By activating GLP-1 receptors in the brain's appetite centers, it increases feelings of fullness and reduces hunger, which tends to lower how many calories you eat. It also slows stomach emptying, so food stays in the stomach longer. Because liraglutide is relatively short-acting, it must be injected once every day, unlike newer once-weekly GLP-1 drugs.

In the pivotal 72-week SURMOUNT-1 trial (2,539 adults with obesity or overweight, without type 2 diabetes; published in the New England Journal of Medicine in 2022), tirzepatide produced average body-weight reductions of about 16.0% at 5 mg, 21.4% at 10 mg, and 22.5% at 15 mg, versus roughly 2.4% with placebo. In the head-to-head SURMOUNT-5 trial (751 participants, 72 weeks, NEJM 2025), Zepbound beat Wegovy (semaglutide) with an average 20.2% weight loss versus 13.7%, a 47% greater relative reduction; about 31.6% of Zepbound users lost at least 25% of their body weight versus 16.1% on Wegovy. Zepbound is also FDA-approved (December 2024) for moderate-to-severe obstructive sleep apnea in adults with obesity, where the SURMOUNT-OSA program showed clinically meaningful reductions in the apnea-hypopnea index versus placebo. Individual results vary with dose, diet, and activity.

In the pivotal SCALE Obesity and Prediabetes trial (NEJM, 2015), adults without diabetes lost a mean of 8.0% of body weight on liraglutide 3.0 mg versus 2.6% on placebo at 56 weeks. About 63% of liraglutide patients lost at least 5% of body weight (vs. 27% on placebo) and roughly 33% lost at least 10% (vs. 11% on placebo). However, in the head-to-head STEP 8 trial (JAMA, 2022), once-weekly semaglutide 2.4 mg produced 15.8% mean weight loss versus 6.4% for daily liraglutide 3.0 mg over 68 weeks, more than double the effect. Individual results vary and depend heavily on combining the drug with diet and activity.

The most common side effects are gastrointestinal and tend to appear during dose increases: nausea (reported in roughly 25-30% of users across the pivotal trials, and as high as the mid-30s in some studies), diarrhea, vomiting, constipation, abdominal pain, indigestion, and fatigue or injection-site reactions. These are usually mild-to-moderate and ease over time with slow titration, though they lead a small percentage of people to stop treatment. Less common but serious risks include pancreatitis (severe persistent abdominal pain), gallbladder problems including gallstones, acute kidney injury (often from dehydration due to vomiting or diarrhea), severe allergic reactions, and low blood sugar when combined with insulin or sulfonylureas. Zepbound carries an FDA boxed warning for thyroid C-cell tumors seen in rodent studies; whether it causes them in humans is unknown, but it is contraindicated in people with a personal or family history of medullary thyroid cancer or MEN 2. Seek care promptly for severe stomach pain, signs of an allergic reaction, or vision changes.

The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, constipation, and abdominal pain, typically mild-to-moderate and worst during the first weeks as the dose is increased. Headache, low blood sugar (especially in people with type 2 diabetes), increased heart rate, and injection-site reactions also occur. Serious but uncommon risks include acute pancreatitis, gallbladder disease (gallstones), and kidney problems from dehydration. Saxenda carries an FDA boxed warning for thyroid C-cell tumors based on rodent studies; whether this risk applies to humans is not known. Seek urgent medical care for severe, persistent abdominal pain, signs of an allergic reaction, or a lump or swelling in the neck.

As of September 2026, LillyDirect's regular self-pay price for a one-month Zepbound KwikPen supply is $299 for 2.5 mg, $399 for 5 mg, $499 for 7.5 mg and $699 for 10 mg, 12.5 mg or 15 mg; Lilly's Zepbound Journey Program can lower the higher-dose prices if you refill on schedule. Self-pay pricing can't be combined with insurance. With commercial insurance that covers Zepbound, Lilly's savings card can reduce the copay for eligible patients (monthly and annual caps apply). Coverage for weight loss varies by plan, so confirm your own benefits before starting, and budget for an ongoing monthly cost — it is a long-term medication.

As of 2026, Saxenda's cash price without insurance runs roughly $1,300 to $1,650 per month for a 30-day supply (five prefilled pens), varying by pharmacy. Pharmacy discount coupons (e.g., GoodRx) can cut this to around $370-$500. Insurance coverage is inconsistent, often requires prior authorization, and many commercial plans, plus Medicare, exclude weight-loss drugs entirely. Note that Novo Nordisk's $25 Saxenda Savings Card was discontinued for new enrollees in mid-2023, so it is no longer a reliable way to lower cost; uninsured patients with limited income may instead qualify for free medication through the Novo Nordisk Patient Assistance Program. A lower-cost generic liraglutide (from Teva) launched in the US in 2025 at roughly $1,165 per month, which may reduce out-of-pocket costs over time as availability expands.

Zepbound is approved for adults with obesity (BMI 30 or higher) or overweight (BMI 27 or higher) plus at least one weight-related condition such as high blood pressure, high cholesterol, or type 2 diabetes, and for moderate-to-severe obstructive sleep apnea in adults with obesity. It is meant to be used alongside a reduced-calorie diet and more physical activity. Do NOT use it if you or a family member has had medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or if you have had a serious allergic reaction to tirzepatide. It is not for use in pregnancy and is not approved for children. Use caution with a history of pancreatitis, gallbladder disease, kidney problems, or severe gastrointestinal disease, and tell your doctor if you take insulin or sulfonylureas (which raise low-blood-sugar risk). Your prescriber makes the final eligibility call.

Saxenda is FDA-approved for adults with obesity (BMI 30 or higher) or with a BMI of 27 or higher plus at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol, and for adolescents aged 12-17 who weigh more than 132 lbs (60 kg) and have obesity. It is meant to be used alongside a reduced-calorie diet and increased physical activity. It is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2), in pregnancy, and in people with a prior serious allergic reaction to liraglutide. It should not be combined with other GLP-1 medicines and is used cautiously in those with a history of pancreatitis or gallbladder disease. Your prescriber makes the final eligibility decision.